TCR-Engineered T Cell Immunotherapy for Epithelial Ovarian Cancer Enhanced by TGFbeta Blockade and Epigenetic Modulation

Abstract

This is a project to test the hypothesis that the combination of epigenetic modification (Decitabine) and adoptive cell therapy (ACT) of NY- ESO-1 TCR/ dnTGFBetaRII engineered T cells will be safe and show improved clinical responses in women who have recurrent/persistent platinum-resistant ovarian cancers. We had successfully reached the milestones for the first year: We injected the highest dose of T cell (10e9 transgenic T cells) in the last cohort of our Phase I clinical trial with NY-ESO-1 TCR/dnTGFBetaRII engineered T cells for solid- tumors (including Ovarian Ca.) FDA approval (IND 17410), (clinicaltrials.gov reg. NCT02650986). And we successfully got approval from IRB and FDA to add Decitabine to the clinical trial as proposed.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2019
Accession Number
AD1107364

Entities

People

  • Richard Koya

Organizations

  • Roswell Park Comprehensive Cancer Center

Tags

DTIC Thesaurus Topics

  • Biomedical Research
  • Blood
  • Cancer
  • Cells
  • Clinical Trials
  • Department Of Defense
  • Immunotherapy
  • Lymphocytes
  • Medical Personnel
  • Neoplasms
  • Ovarian Cancer
  • Platinum
  • Professional Development
  • Technology Transfer

Fields of Study

  • Biology
  • Medicine

Readers

  • Clinical Trial Research.
  • Oncology (Cancer Research).

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech